- Home
- MB vs CABA Comparison
MB vs CABA Comparison
Compare MB & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MB
- CABA
- Stock Information
- Founded
- MB 2019
- CABA 2017
- Country
- MB Hong Kong
- CABA United States
- Employees
- MB N/A
- CABA N/A
- Industry
- MB
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MB
- CABA Health Care
- Exchange
- MB NYSE
- CABA Nasdaq
- Market Cap
- MB 152.0M
- CABA 157.4M
- IPO Year
- MB 2025
- CABA 2019
- Fundamental
- Price
- MB $12.95
- CABA $1.74
- Analyst Decision
- MB
- CABA Strong Buy
- Analyst Count
- MB 0
- CABA 7
- Target Price
- MB N/A
- CABA $14.43
- AVG Volume (30 Days)
- MB 123.3K
- CABA 2.4M
- Earning Date
- MB 01-01-0001
- CABA 08-07-2025
- Dividend Yield
- MB N/A
- CABA N/A
- EPS Growth
- MB N/A
- CABA N/A
- EPS
- MB 0.33
- CABA N/A
- Revenue
- MB $64,882,581.00
- CABA N/A
- Revenue This Year
- MB N/A
- CABA N/A
- Revenue Next Year
- MB N/A
- CABA N/A
- P/E Ratio
- MB $33.83
- CABA N/A
- Revenue Growth
- MB N/A
- CABA N/A
- 52 Week Low
- MB $2.73
- CABA $0.99
- 52 Week High
- MB $15.77
- CABA $8.77
- Technical
- Relative Strength Index (RSI)
- MB N/A
- CABA 52.45
- Support Level
- MB N/A
- CABA $1.43
- Resistance Level
- MB N/A
- CABA $1.68
- Average True Range (ATR)
- MB 0.00
- CABA 0.11
- MACD
- MB 0.00
- CABA 0.00
- Stochastic Oscillator
- MB 0.00
- CABA 86.25
About MB MASTERBEEF GROUP
Masterbeef Group is a full-service restaurant group in Hong Kong, specializing in Taiwanese hotpot and Taiwanese barbecue. The company operates restaurant outlets under the Master Beef and Anping Grill brands. The company operates under a single operating segment, that is the catering service.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.